Recent contributions
Pharmaceutical companies with R&D in Germany – Benefit for price negotiations
Figure 1: Different price guidelines apply for the AMNOG price negotiations if ≥ 5 % of
European Reference Pricing is discontinued in Germany
Figure 1: Number of reference prices used by each country Changes to the German pricing
Confidential reimbursement amount – Only for pharmaceutical companies with R&D in Germany
Figure 1: Requirements, pros and cons for the confidential reimbursement amount in Germany Confidential reimbursement
Our new AMNOG Negotiation Guide is online now!
With the SHI Financial Stabilisation Act (GKV-FinStG), the framework conditions for price negotiations for medicinal products in
Non-randomised studies and non-adjusted indirect comparisons
Overview of our services in the field of non-randomised studies and indirect comparisons Strategic consulting Systematic research
Introduction of confidential reimbursement prices sets the wrong incentives!
We are pleased to inform you that our analysis of confidential reimbursement prices in Germany has been
Transition to EU HTA – Consequences of an existence of national and EU HTA in parallel
Overview of our services Strategic advice Regulation (EU) 2021/2282 Article 7 (1) of Regulation (EU) 2021/2282
Confidentiality of the reimbursement amount has its price!
As part of the dialogue with the pharmaceutical industry, the German government has promised to introduce the option
Price negotiations with the SHI under consideration of the legal changes
SAVE THE DATE: 16.01.2024 From 10:00 am to 11:30 am Speakers: Dr. Willi Schnorpfeil, Dr. Angela Lammert We
Our HospitalAnalyzer is now available!
Based on the quality assurance data of the G-BA, we provide analyses on German hospitals for your market
Further specifications on the GKV-FinStG law
In their 2nd and 3rd reading, the German Parliament has decided further specifications of the new law on
Pharmabarometer Update
Have a look at our latest update of German price negotiations for drugs that went through the AMNOG
GKV-FinStG cabinet decision: Power shift in favor of the statutory health insurance companies expected
The German cabinet, the coalition group of ministers, has decided to introduce the draft bill on the financial
GKV-FinStG draft law: The status of the comparator will impact the outcome of price negotiations
Recently, the German Federal Ministry of Health has published a draft law on the financial stabilization of the
GKV-FinStG draft law: Power shift in favor of the statutory health insurance companies expected
The German Federal Ministry of Health has published a draft law on the financial stabilization of the statutory
EU-HTA: Open call for Joint Scientific Consultations
EUnetHTA21 offers early dialogue Joint Scientific Consultations (JSC) in parallel to the EMA scientific advice for medicinal products
Challenges and Chances of the EU-HTA
The first medicinal products used to treat oncologic diseases and ATMPs will be assessed within the framework of
EU-HTA: Regulation 2021/2282 is effective starting today
The Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health
EU-HTA: Adoption of the Regulation
On Dec 13th, 2021, the Regulation on Health Technology Assessment (HTA) has officially been adopted. The new Regulation
EUnetHTA 21 – Open call for Joint Scientific Consultations
This month, the European Council adopted the regulation on the EU-wide assessment of health technologies (EU-HTA). At the
